Oncology · Desmoid Tumor

Managing Desmoid Tumors: A Critical Component of Care

At a Glance

For Gardner syndrome patients, desmoid tumors are locally aggressive growths that are no longer routinely treated with surgery due to high recurrence risks. The modern standard of care is active surveillance or targeted medications like nirogacestat and sorafenib to safely manage the tumor.

In about 10% to 15% of people with Gardner syndrome, the body may develop desmoid tumors (also called desmoid-type fibromatosis) ^[1]^[2]. While the word “tumor” is frightening, it is important to understand what a desmoid is—and what it is not.

A desmoid tumor is not cancer in the traditional sense because it does not metastasize (spread to distant organs like the lungs or brain) ^[3]. However, it is “locally aggressive,” meaning it can grow into nearby tissues like a tree root, which can cause pain or interfere with how your organs work ^[4]^[5].

The Surgery Paradox

FAP and Gardner syndrome patients face a difficult paradox. The life-saving prophylactic surgery needed to prevent colon cancer is one of the most common triggers for new abdominal desmoid tumors ^[6]^[7]. The physical trauma to the abdominal wall and internal tissues from the colectomy can cause the body to “overheal,” resulting in a desmoid tumor.

The Modern Shift: “Watchful Waiting”

In the past, doctors often rushed to perform surgery to remove desmoid tumors. Today, medical consensus has shifted significantly ^[3]^[8].

Surgery is no longer the first choice: Research has shown that surgery for a desmoid tumor often has a high rate of local recurrence (the tumor coming back in the same spot), sometimes within months ^[8]^[9]. In some cases, the trauma of the surgery itself can trigger a desmoid to grow faster ^[7].
Active Surveillance: For most patients, the new standard of care is active surveillance ^[3]^[10]. This means your team will monitor the tumor closely using MRI or CT scans. If the tumor stays small and doesn’t cause pain, “watching and waiting” is often the safest path to preserve your quality of life ^[11]^[12].

Advanced Medical Therapies

If a desmoid tumor begins to grow or cause significant symptoms, doctors now have powerful medical options that were not available just a few years ago. These treatments aim to stabilize or shrink the tumor without the need for a scalpel ^[13]^[14].

Nirogacestat: This is a groundbreaking drug known as a gamma-secretase inhibitor. It was specifically designed to block the signals that tell desmoid cells to grow ^[15]^[16]. In clinical trials, it significantly slowed tumor progression and improved pain and daily function for many patients ^[13]^[17].
Sorafenib: This is a tyrosine kinase inhibitor, a type of targeted therapy that cuts off the “fuel supply” (blood vessels and growth signals) to the tumor ^[18]^[19].

Why You Need a Sarcoma Specialist

Desmoid tumors are rare, and desmoids within Gardner syndrome are even more specialized ^[1]. Because the management of these tumors has changed so rapidly, it is vital to have a sarcoma specialist on your care team.

Sarcoma specialists are experts in tumors of the connective tissue. They are the most likely to be familiar with the newest medications and the “active surveillance” protocols that can help you avoid unnecessary surgeries ^[14]^[20].

Summary of Desmoid Care

Strategy	Goal	Why it’s used
Active Surveillance	Avoid surgery	Desmoids often stabilize or shrink on their own ^[3].
Nirogacestat	Shrink or stop growth	A modern, targeted pill for progressing tumors ^[13].
Sorafenib	Cut off tumor fuel	A targeted therapy for tumors that are growing ^[18].
Surgery	Symptom relief	Now used only as a last resort in very specific cases ^[21].

Common questions in this guide

What is a desmoid tumor in Gardner syndrome?

A desmoid tumor is a locally aggressive growth of connective tissue that can occur in people with Gardner syndrome. While it does not metastasize or spread like traditional cancer, it can grow into nearby organs and cause pain or functional issues.

Why is surgery no longer the first choice for treating desmoid tumors?

Medical consensus has shifted away from surgery because it has a high rate of local recurrence. In many cases, the physical trauma from surgery can actually trigger a desmoid tumor to grow faster or cause new tumors to form.

What does "active surveillance" mean for a desmoid tumor?

Active surveillance, or watchful waiting, involves closely monitoring the tumor with regular MRI or CT scans rather than treating it immediately. Because many desmoid tumors stabilize or shrink on their own, this approach safely preserves your quality of life while avoiding unnecessary surgery.

What new medical therapies are available for desmoid tumors?

If a tumor grows or causes severe symptoms, doctors may use targeted medications like nirogacestat or sorafenib. These drugs work by blocking growth signals or cutting off the tumor's blood supply to shrink or stabilize it without the need for a scalpel.

Why do I need a sarcoma specialist to treat my desmoid tumor?

Desmoid tumors are rare and complex to manage, especially within Gardner syndrome. A sarcoma specialist has deep expertise in connective tissue tumors and is highly familiar with the latest targeted therapies and active surveillance protocols.

Curated prompts to bring to your next appointment.

1.Given my Gardner syndrome diagnosis, is this tumor considered 'intra-abdominal,' and what specific risks does that pose for my digestive tract?
2.What is the current 'wait and watch' protocol for this tumor—how often will I need an MRI?
3.If the tumor begins to grow or cause pain, are you prepared to prescribe nirogacestat or sorafenib, or should I see a sarcoma specialist?
4.Does my specific APC gene mutation (at codon 1550 or others) suggest I am at a higher risk for aggressive desmoid behavior?
5.How will surgery for my colon polyps (like an IPAA) affect the risk of a desmoid tumor developing or growing?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (21)

1
A novel large deletion in the APC gene associated with Gardner syndrome in a Chinese family.
Zhou J, Liang C, Qing D, et al.
Revista espanola de enfermedades digestivas 2021; (113(3)):179-182 doi:10.17235/reed.2020.6974/2020.
PMID: 33213169
2
Current management of familial adenomatous polyposis.
Lauricella S, Rausa E, Pellegrini I, et al.
Expert review of anticancer therapy 2024; (24(6)):363-377 doi:10.1080/14737140.2024.2344649.
PMID: 38785081
3
Desmoid-type fibromatosis: toward a holistic management.
Penel N, Kasper B, van Der Graaf WTA
Current opinion in oncology 2021; (33(4)):309-314 doi:10.1097/CCO.0000000000000743.
PMID: 33973549
4
Highly aggressive thoracic desmoid tumors in adolescent siblings with fatal outcomes in an FAP kindred: a need for increased vigilance and intervention in at-risk AYAs.
Gad MM, Langevin AM, Sugalski AJ, Tomlinson GE
Familial cancer 2020; (19(4)):311-314 doi:10.1007/s10689-020-00177-2.
PMID: 32281046
5
Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution.
Seidensaal K, Harrabi SB, Weykamp F, et al.
Radiation oncology (London, England) 2020; (15(1)):143 doi:10.1186/s13014-020-01565-9.
PMID: 32503580
6
Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis.
Koskenvuo L, Peltomäki P, Renkonen-Sinisalo L, et al.
Journal of surgical oncology 2016; (113(2)):209-12 doi:10.1002/jso.24117.
PMID: 26663236
7
Case report: Rapidly progressive desmoid tumor after surgery for esophagogastric junction cancer and slowly progressive primary desmoid tumor: a report of two cases and literature review.
Li CY, Gao YP, Jia MH, et al.
Frontiers in oncology 2024; (14()):1401839 doi:10.3389/fonc.2024.1401839.
PMID: 38800396
8
Trends in diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: Japanese musculoskeletal oncology group questionnaire survey.
Murase F, Nishida Y, Hamada S, et al.
Japanese journal of clinical oncology 2021; (51(11)):1615-1621 doi:10.1093/jjco/hyab146.
PMID: 34530455
9
Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.
Yu A, Butler Z, Honore L, et al.
Cancer investigation 2025; (43(4)):257-266 doi:10.1080/07357907.2025.2493240.
PMID: 40257206
10
Desmoid-Type Fibromatosis: Evolving Treatment Standards.
Fiore M, MacNeill A, Gronchi A, Colombo C
Surgical oncology clinics of North America 2016; (25(4)):803-26.
PMID: 27591500
11
Evaluating Management of Extra-Abdominal Desmoid Fibromatosis: A Retrospective Analysis of Treatments, Outcomes and Recurrence Patterns.
Saraf V, Triplicane Dwarakanathan H, Al-Abri AM, et al.
Current oncology (Toronto, Ont.) 2025; (32(6)) doi:10.3390/curroncol32060320.
PMID: 40558263
12
Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.
van Broekhoven DLM, Verschoor AJ, van Dalen T, et al.
Sarcoma 2018; (2018()):5982575 doi:10.1155/2018/5982575.
PMID: 30034268
13
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M, Ratan R, Alcindor T, et al.
The New England journal of medicine 2023; (388(10)):898-912 doi:10.1056/NEJMoa2210140.
PMID: 36884323
14
Current Management of Desmoid Tumors: A Review.
Kasper B, Baldini EH, Bonvalot S, et al.
JAMA oncology 2024; (10(8)):1121-1128 doi:10.1001/jamaoncol.2024.1805.
PMID: 38900421
15
Nirogacestat and its potential impact on desmoid tumor.
Rohail S, Fareed A, Taimuri MA, Adnan A
Rare tumors 2023; (15()):20363613231182485 doi:10.1177/20363613231182485.
PMID: 37325381
16
NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours.
Loong HH, Gupta A, Gronchi A
Annals of surgical oncology 2023; (30(5)):2570-2573 doi:10.1245/s10434-022-12924-z.
PMID: 36907961
17
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Ratan R, Kasper B, Alcindor T, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(34)):3646-3651 doi:10.1200/JCO-25-00582.
PMID: 41115259
18
Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.
Campos F, Kasper B
Expert opinion on pharmacotherapy 2024; (25(16)):2115-2124 doi:10.1080/14656566.2024.2418416.
PMID: 39414771
19
Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.
Tansir G, Rastogi S, Gounder MM
Future oncology (London, England) 2025; (21(23)):2985-2993 doi:10.1080/14796694.2025.2550826.
PMID: 40888418
20
Desmoid tumors: Old and new drugs for a rare and challenging disease.
Kasper B
Cancer 2025; (131(1)):e35603 doi:10.1002/cncr.35603.
PMID: 39545335
21
Paraspinal Desmoid Tumor in a Pediatric Patient with No Surgical History: A Case Report.
Patel A, Varga G, Mallela AN, et al.
Asian journal of neurosurgery 2024; (19(1)):87-93 doi:10.1055/s-0043-1771366.
PMID: 38751393

This page provides educational information about managing desmoid tumors in Gardner syndrome. Always consult a sarcoma specialist or your oncology team for personalized treatment and surveillance advice.

Get notified when new evidence is published on Gardner syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents